Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 2/20 | 0.36 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.36 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.36 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.36 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.36 |
| ▸ | AQP1 | P29972 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4230888 | 0.91 | PRKAB2 (0.45) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4223586 | 0.87 | PRKAB2 (0.42) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4222416 | 0.84 | AQP1 (0.47) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4226127 | 0.84 | AQP1 (0.46) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4225490 | 0.83 | AQP1 (0.50) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4224670 | 0.83 | PRKAB2 (0.42) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4230319 | 0.83 | PRKAB2 (0.43) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4227074 | 0.82 | PRKAB2 (0.42) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4711421 | 0.82 | ALDH1A1 (0.38) | MAOB | |
| SCHEMBL4232163 | 0.81 | PRKAB2 (0.41) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435837-B2 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2008-10-14 | — | — | US | claimed |
| US-7396857-B2 | Therapeutic combinations for the treatment or prevention of depression | WYETH (US) | 2008-07-08 | — | — | US | claimed |
| EP-1874292-A2 | METHODS FOR MODULATING BLADDER FUNCTION | Wyeth (US) | 2008-01-09 | — | — | EP | claimed |
| EP-1871354-A1 | TREATMENT OF PAIN | Wyeth (US) | 2008-01-02 | — | — | EP | claimed |
| US-20070225334-A1 | Methods for treating cognitive and other disorders | WYETH (US) | 2007-09-27 | — | — | US | claimed |
| US-20060258712-A1 | Methods for modulating bladder function | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| US-20060258739-A1 | Dihydrobenzofuran derivatives and uses therof | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| US-20060258711-A1 | Treatment of drug abuse | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| US-20060258639-A1 | Therapeutic combinations for the treatment or prevention of psychotic disorders | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| US-20060258715-A1 | Therapeutic combinations for the treatment or prevention of depression | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| US-20060258713-A1 | Treatment of pain | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| WO-2006116169-A2 | METHODS FOR MODULATING BLADDER FUNCTION | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| WO-2006116171-A1 | TREATMENT OF PAIN | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | claimed |
| US-20090082434-A1 | Dihydrobenzofuranyl Alkanamine Derivatives and Methods for Using Same | WYETH (US) | 2009-03-26 | — | — | US | disclosed |
| US-20080269321-A1 | Therapeutic Combinations for the Treatment or Prevention of Depression | WYETH (US) | 2008-10-30 | — | — | US | disclosed |
| US-7435837-B2 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2008-10-14 | — | — | US | disclosed |
| WO-2006116221-A2 | THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-11-24 | — | — | US | disclosed |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258715-A1 | Therapeutic combinations for the treatment or prevention of depression | GRIN3A, GRIN2A, BDNF | PRKAB2 3384/4885PRKAG1 3443/4885PRKAA2 3940/4885 |
| US-20060258639-A1 | Therapeutic combinations for the treatment or prevention of psychotic disorders | TTPA, GAP43, SLC6A3 | PRKAB2 3768/4885PRKAG1 3769/4885PRKAA2 4325/4885 |
| US-20060258711-A1 | Treatment of drug abuse | OPRK1, OPRM1, ADH1A | PRKAB2 2840/4885PRKAG1 2552/4885PRKAA2 3592/4885 |
| US-20070225334-A1 | Methods for treating cognitive and other disorders | CHAT, COMT, ACHE | PRKAB2 2928/4885PRKAG1 3153/4885PRKAA2 4581/4885 |
| US-20060258739-A1 | Dihydrobenzofuran derivatives and uses therof | HTR1F, HTR2C, HTR3D | PRKAB2 4363/4885PRKAG1 4343/4885PRKAA2 3304/4885 |
| US-20090082434-A1 | Dihydrobenzofuranyl Alkanamine Derivatives and Methods for Using Same | HTR2C, HTR1A, HTR3A | PRKAB2 2598/4885PRKAG1 2441/4885PRKAA2 1756/4885 |
| US-20060258713-A1 | Treatment of pain | OPRL1, OPRK1, OPRD1 | PRKAB2 2785/4885PRKAG1 2694/4885PRKAA2 4145/4885 |
| US-20060258712-A1 | Methods for modulating bladder function | PDE3A, PDE3B, PDE2A | PRKAB2 1021/4885PRKAG1 1420/4885PRKAA2 3163/4885 |
| US-20080269321-A1 | Therapeutic Combinations for the Treatment or Prevention of Depression | GRIN3A, GRIN2A, BDNF | PRKAB2 3384/4885PRKAG1 3443/4885PRKAA2 3940/4885 |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | HTR2C, HTR1A, HTR3A | PRKAB2 2598/4885PRKAG1 2441/4885PRKAA2 1756/4885 |
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | ADRA2A, HTR2A, ADRA1A | PRKAB2 2184/4885PRKAG1 2809/4885PRKAA2 1346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.